BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 9817627)

  • 1. Effect of adjuvant pindolol on the antiobsessional response to fluvoxamine: a double-blind, placebo-controlled study.
    Mundo E; Guglielmo E; Bellodi L
    Int Clin Psychopharmacol; 1998 Sep; 13(5):219-24. PubMed ID: 9817627
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of fluvoxamine, paroxetine, and citalopram in the treatment of obsessive-compulsive disorder: a single-blind study.
    Mundo E; Bianchi L; Bellodi L
    J Clin Psychopharmacol; 1997 Aug; 17(4):267-71. PubMed ID: 9241005
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low-dose risperidone augmentation of fluvoxamine treatment in obsessive-compulsive disorder: a double-blind, placebo-controlled study.
    Erzegovesi S; Guglielmo E; Siliprandi F; Bellodi L
    Eur Neuropsychopharmacol; 2005 Jan; 15(1):69-74. PubMed ID: 15572275
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Faster onset of action of fluvoxamine in combination with pindolol in the treatment of delusional depression: a controlled study.
    Zanardi R; Franchini L; Gasperini M; Lucca A; Smeraldi E; Perez J
    J Clin Psychopharmacol; 1998 Dec; 18(6):441-6. PubMed ID: 9864075
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A double-blind study of fluvoxamine and clomipramine in the treatment of obsessive-compulsive disorder.
    Milanfranchi A; Ravagli S; Lensi P; Marazziti D; Cassano GB
    Int Clin Psychopharmacol; 1997 May; 12(3):131-6. PubMed ID: 9248868
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pindolol augmentation in treatment-resistant obsessive compulsive disorder: a double-blind placebo controlled trial.
    Dannon PN; Sasson Y; Hirschmann S; Iancu I; Grunhaus LJ; Zohar J
    Eur Neuropsychopharmacol; 2000 May; 10(3):165-9. PubMed ID: 10793318
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Specificity of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder. Comparison of fluvoxamine and desipramine.
    Goodman WK; Price LH; Delgado PL; Palumbo J; Krystal JH; Nagy LM; Rasmussen SA; Heninger GR; Charney DS
    Arch Gen Psychiatry; 1990 Jun; 47(6):577-85. PubMed ID: 2112374
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. A double-blind, placebo-controlled study in patients with and without tics.
    McDougle CJ; Goodman WK; Leckman JF; Lee NC; Heninger GR; Price LH
    Arch Gen Psychiatry; 1994 Apr; 51(4):302-8. PubMed ID: 8161290
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine.
    Smeraldi E; Zanardi R; Benedetti F; Di Bella D; Perez J; Catalano M
    Mol Psychiatry; 1998 Nov; 3(6):508-11. PubMed ID: 9857976
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Memantine add-on in moderate to severe obsessive-compulsive disorder: randomized double-blind placebo-controlled study.
    Ghaleiha A; Entezari N; Modabbernia A; Najand B; Askari N; Tabrizi M; Ashrafi M; Hajiaghaee R; Akhondzadeh S
    J Psychiatr Res; 2013 Feb; 47(2):175-80. PubMed ID: 23063327
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A controlled trial of fluvoxamine in obsessive-compulsive disorder: implications for a serotonergic theory.
    Jenike MA; Hyman S; Baer L; Holland A; Minichiello WE; Buttolph L; Summergrad P; Seymour R; Ricciardi J
    Am J Psychiatry; 1990 Sep; 147(9):1209-15. PubMed ID: 2143637
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined fluvoxamine and extended-release methylphenidate improved treatment response compared to fluvoxamine alone in patients with treatment-refractory obsessive-compulsive disorder: A randomized double-blind, placebo-controlled study.
    Zheng H; Jia F; Han H; Wang S; Guo G; Quan D; Li G; Huang H
    Eur Neuropsychopharmacol; 2019 Mar; 29(3):397-404. PubMed ID: 30595354
    [TBL] [Abstract][Full Text] [Related]  

  • 13. L-carnosine as an adjuvant to fluvoxamine in treatment of obsessive compulsive disorder: A randomized double-blind study.
    Arabzadeh S; Shahhossenie M; Mesgarpour B; Rezaei F; Shalbafan MR; Ghiasi Z; Akhondzadeh S
    Hum Psychopharmacol; 2017 Jul; 32(4):. PubMed ID: 28485008
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A controlled trial of lithium augmentation in fluvoxamine-refractory obsessive-compulsive disorder: lack of efficacy.
    McDougle CJ; Price LH; Goodman WK; Charney DS; Heninger GR
    J Clin Psychopharmacol; 1991 Jun; 11(3):175-84. PubMed ID: 1820757
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A double-blind, placebo-controlled study of the efficacy and safety of controlled-release fluvoxamine in patients with obsessive-compulsive disorder.
    Hollander E; Koran LM; Goodman WK; Greist JH; Ninan PT; Yang H; Li D; Barbato LM
    J Clin Psychiatry; 2003 Jun; 64(6):640-7. PubMed ID: 12823077
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An open study of fluvoxamine augmentation of neuroleptics in schizophrenia with obsessive and compulsive symptoms.
    Reznik I; Sirota P
    Clin Neuropharmacol; 2000; 23(3):157-60. PubMed ID: 10895399
    [TBL] [Abstract][Full Text] [Related]  

  • 17. L-theanine combination therapy with fluvoxamine in moderate-to-severe obsessive-compulsive disorder: A placebo-controlled, double-blind, randomized trial.
    Nematizadeh M; Ghorbanzadeh H; Moghaddam HS; Shalbafan M; Boroon M; Keshavarz-Akhlaghi AA; Akhondzadeh S
    Psychiatry Clin Neurosci; 2023 Sep; 77(9):478-485. PubMed ID: 37169515
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Riluzole in augmentation of fluvoxamine for moderate to severe obsessive-compulsive disorder: Randomized, double-blind, placebo-controlled study.
    Emamzadehfard S; Kamaloo A; Paydary K; Ahmadipour A; Zeinoddini A; Ghaleiha A; Mohammadinejad P; Zeinoddini A; Akhondzadeh S
    Psychiatry Clin Neurosci; 2016 Aug; 70(8):332-41. PubMed ID: 27106362
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of fluvoxamine and behavior therapy on children and adolescents with obsessive-compulsive disorder.
    Neziroglu F; Yaryura-Tobias JA; Walz J; McKay D
    J Child Adolesc Psychopharmacol; 2000; 10(4):295-306. PubMed ID: 11191690
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of obsessive-compulsive disorder with fluvoxamine: a multicentre, double-blind, placebo-controlled trial.
    Goodman WK; Kozak MJ; Liebowitz M; White KL
    Int Clin Psychopharmacol; 1996 Mar; 11(1):21-9. PubMed ID: 8732310
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.